CEO Todd Zavodnick (Dermavant)

With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

In the next cou­ple months, Der­ma­vant CEO Todd Za­vod­nick says he’ll sprint to the FDA with tap­inarof, the com­pa­ny’s “cos­met­i­cal­ly el­e­gant” van­ish­ing cream to treat pso­ri­a­sis. But be­fore that, he has more Phase III da­ta to share.

Around 20% of mod­er­ate to se­vere plaque pso­ri­a­sis pa­tients giv­en tap­inarof in two Phase III tri­als achieved 90% dis­ease clear­ance, mea­sured by the Pso­ri­a­sis Area and Sever­i­ty In­dex (PASI 90) at Week 12, Za­vod­nick shared Fri­day at the Amer­i­can Acad­e­my of Der­ma­tol­ogy vir­tu­al meet­ing. And around 67% and 60% of pa­tients in the tri­als felt itch re­lief start­ing as ear­ly as Week 2.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.